probenecid has been researched along with Cardiovascular Diseases in 15 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors conducted a cohort study to examine comparative CV safety of the 2 gout treatments-probenecid and allopurinol-in patients with gout." | 7.88 | Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. ( Desai, RJ; Kang, EH; Kim, SC; Liu, J; Neogi, T; Solomon, DH; Zhang, M, 2018) |
| "The authors conducted a cohort study to examine comparative CV safety of the 2 gout treatments-probenecid and allopurinol-in patients with gout." | 3.88 | Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. ( Desai, RJ; Kang, EH; Kim, SC; Liu, J; Neogi, T; Solomon, DH; Zhang, M, 2018) |
| "Febuxostat is a new xanthine oxidase inhibitor, which will be available for the treatment of refractory gout in the near future." | 2.46 | [The clinical picture of gout is changing]. ( Julkunen, H; Konttinen, YT, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Onódi, Z | 2 |
| Koch, S | 2 |
| Rubinstein, J | 3 |
| Ferdinandy, P | 2 |
| Varga, ZV | 2 |
| Kim, SC | 3 |
| Neogi, T | 2 |
| Kim, E | 1 |
| Lii, J | 1 |
| Desai, RJ | 2 |
| Givertz, MM | 1 |
| Kang, EH | 2 |
| Liu, J | 1 |
| Zhang, M | 1 |
| Solomon, DH | 1 |
| Robbins, N | 1 |
| Koch, SE | 1 |
| Richette, P | 1 |
| Perez-Ruiz, F | 1 |
| Doherty, M | 1 |
| Jansen, TL | 1 |
| Nuki, G | 1 |
| Pascual, E | 1 |
| Punzi, L | 1 |
| So, AK | 1 |
| Bardin, T | 1 |
| Molica, F | 1 |
| Morel, S | 1 |
| Meens, MJ | 1 |
| Denis, JF | 1 |
| Bradfield, PF | 1 |
| Penuela, S | 1 |
| Zufferey, A | 1 |
| Monyer, H | 1 |
| Imhof, BA | 1 |
| Chanson, M | 1 |
| Laird, DW | 1 |
| Fontana, P | 1 |
| Kwak, BR | 1 |
| Julkunen, H | 1 |
| Konttinen, YT | 1 |
| Hisatome, I | 1 |
| EDELMAN, J | 1 |
| KERSHBAUM, A | 1 |
| SANDBERG, H | 1 |
| BELLET, S | 1 |
| LAL, HB | 1 |
| LAL, H | 1 |
| Nikolov, GS | 1 |
| Straus, B | 1 |
| Holländer, E | 1 |
| Schwarczmann, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for probenecid and Cardiovascular Diseases
| Article | Year |
|---|---|
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Drug Repositioning; Heart Failure; Humans; Myocard | 2023 |
Cardiovascular Safety of Urate Lowering Therapies.
Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failur | 2019 |
Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease.
Topics: Animals; Capsaicin; Cardiotonic Agents; Cardiovascular Diseases; Disease Models, Animal; Humans; Mic | 2013 |
Improving cardiovascular and renal outcomes in gout: what should we target?
Topics: Allopurinol; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, Type 2; Disease Management; Gou | 2014 |
[The clinical picture of gout is changing].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2010 |
[Impact of serum uric acid level on the cardiovascular system as a risk factor].
Topics: Adipokines; Benzbromarone; Cardiovascular Diseases; Hyperuricemia; Kidney; Organic Anion Transporter | 2010 |
9 other studies available for probenecid and Cardiovascular Diseases
| Article | Year |
|---|---|
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Drug Labeling; Febuxostat; Gout; Gout Suppress | 2021 |
Treating Gout in Patients With Cardiovascular Disease: Mutual Benefit or Unintended Consequences?
Topics: Aged; Allopurinol; Cardiovascular Diseases; Gout; Humans; Probenecid; Risk Factors | 2018 |
Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.
Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cohort Studies; Female; | 2018 |
Functional role of a polymorphism in the Pannexin1 gene in collagen-induced platelet aggregation.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adolescent; Adult; Alleles; Amino Acid Substitution; | 2015 |
The effect of probenecid administration on blood lipids and lipid tolerance curves in subjects with myocardial infarction.
Topics: Cardiovascular Diseases; Drug Tolerance; Humans; Lipids; Myocardial Infarction; Probenecid | 1961 |
Serum uric acid in myocardial infarction.
Topics: Cardiovascular Diseases; Humans; Myocardial Infarction; Probenecid; Uric Acid | 1963 |
[Podagric arthropathy].
Topics: Adolescent; Adult; Albuminuria; Algeria; Cardiovascular Diseases; Child; Child, Preschool; Cholester | 1971 |
Problems and progress in geriatrics.
Topics: Acute Disease; Aged; Aging; Calcitonin; Cardiovascular Diseases; Chronic Disease; Diabetic Coma; Dia | 1968 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |